pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,705 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive237onclive165Fierce Biotech82BioSpace80raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
    Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...
    Endpoints · 2mo ago↗ source
  • Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
    On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific anti…
    Endpoints · 2mo ago↗ source
  • STAT+: The woman behind the world’s biggest longevity competition
    Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
← prev
page 42 of 69
next →
21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 2mo ago
↗ source
  • Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
    Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
    STAT · 2mo ago↗ source
  • STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
    The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
    STAT · 2mo ago↗ source
  • Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
    Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company announced Thursday that its…
    Endpoints · 2mo ago↗ source
  • For wearables, it’s a GLP-1 world
    We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies. First, Signos raised $20 million for its approach ...
    Endpoints · 2mo ago↗ source
  • ICON audit finds overstated revenue; Secretome and Psilera raise cash
    👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1%…
    Endpoints · 2mo ago↗ source
  • #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
    In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the m…
    Endpoints · 2mo ago↗ source
  • Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm
    Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture a…
    Endpoints · 2mo ago↗ source
  • Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
    Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies…
    Endpoints · 2mo ago↗ source
  • China gene editing startup YolTech raises $70M to move CRISPR therapies forward
    One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
    Endpoints · 2mo ago↗ source
  • Oura pushes deeper into healthcare services as part of new ring launch
    Alongside the debut of Oura's smaller Ring 5, the wearables company on Thursday unveiled its plans to help users integrate health records and translate their ring’s findings into medical care. Oura…
    Endpoints · 2mo ago↗ source
  • AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
    AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...
    Endpoints · 2mo ago↗ source
  • GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
    GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four mark…
    Endpoints · 2mo ago↗ source
  • AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
    Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…
    Endpoints · 2mo ago↗ source
  • STAT+: 23andMe offers to connect users’ DNA data with medical records
    23andMe is partnering with HealthEx to allow users to import their medical records, the company said Tuesday at STAT Breakthrough Summit West.
    STAT · 2mo ago↗ source
  • STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case
    Former Stanford President Marc Tessier-Lavigne responded publicly for the first time, at a STAT event Tuesday, to allegations in a new book about why he was forced to resign.
    STAT · 2mo ago↗ source
  • Trump’s cuts to foreign aid are undermining the Ebola response, insiders say
    President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.
    STAT · 2mo ago↗ source
  • STAT+: Virginia governor vetoes legislation to create an advisory panel to lower the cost of prescription drugs
    Virginia's governor vetoed a closely watched effort to create an advisory panel to lower prescription drug costs.
    STAT · 2mo ago↗ source
  • STAT+: This spine surgery usually costs $1,400. Under No Surprises Act arbitration? $34,000
    A new analysis shows how some clinicians are cashing in on a new process designed to protect patients from surprise bills.
    STAT · 2mo ago↗ source
  • How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’
    The parents of Jorie Kraus told the audience at STAT's Breakthrough Summit West about how AI helped their daughter who was born with a rare disease.
    STAT · 2mo ago↗ source
  • TrumpRx adds hundreds of generic medicines to site
    The Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines. President Donald Trump o…
    Endpoints · 2mo ago↗ source
  • Another Paragon offshoot chooses reverse merger, this time for migraine drugs
    They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the p…
    Endpoints · 2mo ago↗ source
  • Acceleron leaders and Westlake jumpstart new IPF biotech
    After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…
    Endpoints · 2mo ago↗ source